HC Wainwright Issues Optimistic Estimate for MAZE Earnings

Key Points

• HC Wainwright raised its Maze Therapeutics EPS forecasts, now expecting a Q3 2026 loss of $0.70 per share versus its prior estimate of $0.77. The firm maintained a Buy rating and $110 price target.
• Analyst sentiment is generally positive, with Maze receiving an average Buy rating and a consensus price target of $63.40, although estimates still project continued losses through 2030.
• Maze shares opened at $26.43, near their 50-day moving average, while insiders sold approximately $5.15 million of stock over the past 90 days. Institutional investors, including Frazier Life Sciences Management, also increased their holdings.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) - Equities research analysts at HC Wainwright lifted their Q3 2026 EPS estimates for shares of Maze Therapeutics in a research note issued on Monday, October 5th. HC Wainwright analyst A. Ghosh now anticipates that the company will earn ($0.70) per share for the quarter, up from their previous forecast of ($0.77). HC Wainwright has a "Buy" rating and a $110.00 price target on the stock. The consensus estimate for Maze Therapeutics' current full-year earnings is ($2.72) per share. HC Wainwright also issued estimates for Maze Therapeutics' Q4 2026 earnings at ($0.71) EPS, FY2026 earnings at ($2.63) EPS, Q1 2027 earnings at ($0.65) EPS, Q4 2027 earnings at ($0.64) EPS, FY2027 earnings at ($2.60) EPS, FY2028 earnings at ($2.23) EPS, FY2029 earnings at ($2.05) EPS and FY2030 earnings at ($2.16) EPS.

Other research analysts also recently issued research reports about the stock. TD Cowen upgraded shares of Maze Therapeutics to a "strong-buy" rating in a research note on Monday, August 24th. Weiss Ratings reissued a "sell (d-)" rating on shares of Maze Therapeutics in a research report on Monday, September 21st. Citigroup started coverage on Maze Therapeutics in a research note on Wednesday, September 23rd. They issued a "buy" rating and a $50.00 price target on the stock. BTIG Research restated a "buy" rating and set a $46.00 price objective on shares of Maze Therapeutics in a research report on Tuesday, September 22nd. Finally, Wall Street Zen downgraded Maze Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. Three research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Maze Therapeutics has an average rating of "Buy" and a consensus target price of $63.40.

Maze Therapeutics Stock Performance

Shares of Maze Therapeutics stock opened at $26.43 on Wednesday. The business has a 50-day simple moving average of $26.90 and a 200-day simple moving average of $27.74. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. Maze Therapeutics has a one year low of $21.95 and a one year high of $53.65. The company has a market cap of $1.47 billion, a PE ratio of -10.49 and a beta of 2.16.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.76).

Insiders Place Their Bets

In other Maze Therapeutics news, CMO Harold Bernstein sold 16,141 shares of the business's stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $26.93, for a total transaction of $434,677.13. Following the sale, the chief marketing officer directly owned 16,141 shares in the company, valued at approximately $434,677.13. The trade was a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the stock in a transaction dated Tuesday, September 29th. The shares were sold at an average price of $27.06, for a total transaction of $202,950.00. Following the completion of the transaction, the insider owned 32,316 shares of the company's stock, valued at $874,470.96. This represents a 18.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 192,991 shares of company stock valued at $5,152,084 over the last 90 days. 5.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Squarepoint Ops LLC lifted its stake in shares of Maze Therapeutics by 42.8% during the second quarter. Squarepoint Ops LLC now owns 19,434 shares of the company's stock valued at $580,000 after buying an additional 5,822 shares during the period. Frazier Life Sciences Management L.P. boosted its holdings in shares of Maze Therapeutics by 10.2% during the second quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company's stock worth $150,182,000 after purchasing an additional 465,641 shares during the last quarter. AXQ Capital LP grew its position in shares of Maze Therapeutics by 114.1% in the second quarter. AXQ Capital LP now owns 15,193 shares of the company's stock valued at $453,000 after purchasing an additional 8,098 shares during the period. Braidwell LP acquired a new position in Maze Therapeutics in the second quarter valued at $34,019,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Maze Therapeutics by 4,054.3% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 17,739 shares of the company's stock worth $529,000 after buying an additional 17,312 shares during the last quarter.

More Maze Therapeutics News

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: HC Wainwright raised most EPS forecasts. The firm improved its estimates for Q3 2026 to a loss of $0.70 per share from $0.77, Q4 2026 to a loss of $0.71 from $0.80, FY2026 to a loss of $2.63 from $2.81, FY2027 to a loss of $2.60 from $3.27, FY2028 to a loss of $2.23 from $2.89, and FY2029 to a loss of $2.05 from $2.46. Although Maze is still expected to report losses, the revisions suggest analysts see a better earnings trajectory and could support the stock. MarketBeat Maze Therapeutics estimates
• Positive Sentiment: HC Wainwright maintained a Buy rating and $110 price target. The target is substantially above Maze’s recent trading level near its $26.90 50-day moving average, signaling significant potential upside if the company’s clinical programs progress successfully. MarketBeat Maze Therapeutics analyst rating
• Positive Sentiment: Maze will present data at ASN Kidney Week 2026. An oral presentation will feature previously reported Phase 2 HORIZON data for MZE829 in APOL1-mediated kidney disease, while two posters will provide preclinical support for MZE782 and SLC6A19 inhibition in chronic kidney disease. The event could provide a near-term catalyst, although the MZE829 data are not new. Maze Therapeutics ASN Kidney Week announcement
• Neutral Sentiment: HC Wainwright projects continued quarterly losses, including EPS of negative $0.65 in Q1 2027 and Q2-Q3 2027, while the consensus estimate for the current fiscal year remains a loss of $2.72 per share. Investors will continue to focus on clinical progress and cash usage rather than near-term profitability.
• Negative Sentiment: HC Wainwright sharply reduced its FY2030 EPS estimate to a loss of $2.16 per share from a loss of $0.72. The downgrade suggests a more cautious view of Maze’s long-term path toward profitability and partially offsets the nearer-term estimate increases.

Maze Therapeutics Company Profile

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetic diseases. The company uses human genetics and its Maze Compass platform to identify disease-causing biological mechanisms and design small-molecule therapies intended to address the underlying drivers of disease.

Maze's pipeline includes MZE001, an investigational oral therapy designed to inhibit glycogen synthase as a potential treatment for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.